Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Clinical trial NCT03065387 · TERMINATED

Trial details

NCT number: NCT03065387
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Malignant Solid Neoplasm EGFR Gene Amplification EGFR Gene Mutation ERBB2 Gene Amplification ERBB2 Gene Mutation ERBB3 Gene Mutation ERBB4 Gene Mutation KRAS Gene Mutation Metastatic Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm

Start date: 2017-10-31
Primary completion: 2026-04-23
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.